Tectonic Therapeutic, Inc.

NasdaqGM:TECX Stock Report

Market Cap: US$547.0m

Tectonic Therapeutic Management

Management criteria checks 2/4

Tectonic Therapeutic's CEO is Alise Reicin, appointed in Aug 2020, has a tenure of 5.75 years. total yearly compensation is $7.35M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 1.67% of the company’s shares, worth $9.13M. The average tenure of the management team and the board of directors is 4.4 years and 5.8 years respectively.

Key information

Alise Reicin

Chief executive officer

US$7.4m

Total compensation

CEO salary percentage8.72%
CEO tenure5.8yrs
CEO ownership1.7%
Management average tenure4.4yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 16

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Summary Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45’s engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b data. With a $253.8M cash balance, TECX is funded for phase 2; positive topline data in 2026 could unlock a $0.6B–$1.8B U.S. peak sales opportunity. I rate TECX a Buy for its binary, high-upside profile, solid early data, and potential for 2-3x returns if phase 2/3 data confirm efficacy. Read the full article on Seeking Alpha
Analysis Article • Nov 10

Companies Like Tectonic Therapeutic (NASDAQ:TECX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 20

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 23

Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF

Summary We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026. Financially, TECX has a strong cash position to fund operations into late 2028 but faces significant risks if clinical trials do not meet expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 05

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data

Summary Positive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study using TX45 for the treatment of patients with pulmonary hypertension heart failure with reduced ejection fraction, expected in 2nd half of 2025. In the 7 major markets, the heart failure market is expected to grow to $33.7 billion in 2032. TX2100 is another candidate in the company's pipeline which is currently undergoing IND-enabling studies to target patients with Hemorrhagic Telangiectasia; Phase 1 study expected Q4 2025/Q1 2026. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside

Summary Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed promising hemodynamic improvements and safety, potentially addressing both pulmonary and cardiac aspects of PH-HFpEF. Despite concerns over small data sets and past failures of similar drugs, Tectonic's experienced management and promising data make TECX stock an intriguing “Buy” opportunity. Investors may consider waiting for further data or fundraising announcements to mitigate risks, but the potential market opportunity is significant. Read the full article on Seeking Alpha
Analysis Article • Jan 10

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 30

Tectonic Therapeutic: Waiting For A Pullback

Summary Tectonic Therapeutic, Inc. has seen a significant stock rally which has seen its shares nearly triple since this summer. The rally has been driven by analyst optimism and the initiation of Phase 2 trials for its lead asset TX45. This compound has the potential to be a 'best of breed' product for a large untreated population. What is ahead for Tectonic Therapeutic and its shareholders in 2025?  An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 20

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Summary Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027. Despite early-stage development and competition from AstraZeneca, TECX is promising, with strong support from Wells Fargo and a long cash runway. Read the full article on Seeking Alpha
Analysis Article • Sep 22

Here's Why We're Not Too Worried About Tectonic Therapeutic's (NASDAQ:TECX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 05

Tectonic Therapeutic: Analyzing Its Post-Merger Valuation And Prospects

Summary Tectonic Therapeutic, Inc. is a biotechnology company focusing on therapeutic biologics targeting GPCRs through its GEODe platform. TECX emerged after a merger with Avrobio, combining gene therapy expertise with GPCR-targeted protein development. The lead drug candidate, TX45, is in Phase 1 trials for pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF). The company's cash runway is expected to last until mid-2027, potentially necessitating future capital raises. TECX's valuation appears relatively cheap compared to peers, but its early-stage research and cash burn risks lead me to a neutral stance. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Alise Reicin's remuneration changed compared to Tectonic Therapeutic's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$7mUS$641k

-US$74m

Sep 30 2025n/an/a

-US$67m

Jun 30 2025n/an/a

-US$66m

Mar 31 2025n/an/a

-US$59m

Dec 31 2024US$6mUS$606k

-US$58m

Sep 30 2024n/an/a

-US$53m

Jun 30 2024n/an/a

-US$46m

Mar 31 2024n/an/a

-US$44m

Dec 31 2023US$932kUS$575k

-US$43m

Compensation vs Market: Alise's total compensation ($USD7.35M) is above average for companies of similar size in the US market ($USD2.52M).

Compensation vs Earnings: Alise's compensation has increased whilst the company is unprofitable.

CEO

Alise Reicin (64 yo)

5.8yrs
Tenure
US$7,351,578
Compensation

Dr. Alise S. Reicin, MD, PhD, serves as Member of Strategic Advisory Board at SCTbio a.s. (formerly known as Sotio a.s.). since November 2021. She serves on the board of directors of Sana Biotherapeutics a...

Leadership Team

NamePositionTenureCompensationOwnership
Alise Reicin
President5.8yrsUS$7.35m1.67%
$ 9.1m
Daniel Lochner
Chief Financial Officer1.9yrsUS$3.10m0.077%
$ 422.7k
Marcella Ruddy
Chief Medical Officer4.8yrsUS$3.07m0.13%
$ 724.3k
Peter McNamara
Chief Scientific Officer3.9yrsno data0.094%
$ 511.9k
Geraldine Peters-Wiles
Senior Vice President of Human Resourcesless than a yearno datano data
Anthony Muslin
Chief Development Officerno datano datano data
Marc Schwabish
Chief Business Officer5.2yrsno data0.065%
$ 355.6k
John Diener
Senior Vice President of Antibody Engineering & Protein Sciencesno datano datano data
4.4yrs
Average Tenure
53yo
Average Age

Experienced Management: TECX's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alise Reicin
President5.8yrsUS$7.35m1.67%
$ 9.1m
Terrance McGuire
Independent Director6.7yrsUS$280.88k0.11%
$ 588.0k
Timothy Springer
Independent Director6.9yrsUS$248.00k30.97%
$ 169.4m
Phillip Donenberg
Independent Director1.9yrsUS$253.76k0.00088%
$ 4.8k
Francois Nader
Independent Chair of the Boardless than a yearno datano data
Praveen Tipirneni
Independent Director6.3yrsUS$250.00k0.016%
$ 88.1k
Stefan Vitorovic
Independent Director4.8yrsUS$251.88kno data
5.8yrs
Average Tenure
64yo
Average Age

Experienced Board: TECX's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 15:30
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tectonic Therapeutic, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RisingerLeerink Partners LLC
Cory JubinvilleLifeSci Capital, LLC
Uy EarMizuho Securities USA LLC